Discover exclusive news, ideas and insights from across the spectrum of healthcare innovation.

How will you advance healthcare?

Regular

Jesse Shefferman built Protara by reviving drug candidates other companies had shelved, and he runs the company on the same belief: setbacks are rarely fatal.

How Protara Built a Biotech Around Second-Chance Drugs

After 20 years of misdiagnosis, Tamar Zelovich-Hod used the pattern-finding methods from her quantum chemistry research to identify her own endometriosis, then built them into SymptoLab, a decision-support tool for physicians.

How a Quantum Chemist Decoded Her Own Symptoms and Built a Women’s Health Startup

Genomic tools trained on decades of male-dominated data can read female biology as low risk. Startups are building their own datasets to fix it, but researchers say the deeper problem runs through the NIH and the journals.

How Precision Medicine Inherited the Male Default

The race is shifting from how much to what kind of weight patients lose. These nine companies are building on what Ozempic started, betting on pills instead of injections, drugs that spare muscle, and uses well beyond obesity.

Biotech Companies Developing Next-Generation GLP-1 Drugs

9 Companies Developing Next-Generation GLP-1 Drugs

China has caught up to the United States on the volume of biomedical research, but American universities and research institutions still hold a wide lead on influence.

The U.S. Leads China in the Science That Matters Most

The US Still Leads China in Biomedical Influence, and These Are the Institutions Behind It

A survey of 303 US institutions reveals how access to foundational vs. frontier core labs shapes translational success.

CII White Paper - The Labs Behind the Deals Core Technologies - Image

Cure Original Report: The Core Labs Behind the Deals

Searching for cures and therapies for rare diseases is no longer a niche market. Instead, it has become a major sector of biotech. Here are 11 companies that are leading the way.

Companies Advancing Treatments for Rare Diseases thumbnail

11 Companies Advancing Treatments for Rare Diseases

Venture capital is flooding into menopause, just not into the provider training and clinical access that could make a real difference for patient and their care providers.

Menopause funding piece - Image

Is the Menopause Investment Boom Missing the Point?

The latest longevity biotech funding news, updated monthly—tracking major rounds and non-dilutive awards of $10M or more in 2026.

Cure’s Longevity Biotech Funding Tracker 2026

The latest AI drug discovery venture capital news, updated monthly—tracking funding rounds of $10M or more in 2026.

Cure’s AI Drug Discovery Funding Tracker 2026

How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.

Inside the Structural Reforms That Made IU Indianapolis a Translational Overachiever

The science is winning over investors. But the harder question is whether companies can turn aging biology into drugs that sell, and businesses that last.

Building a longevity company: What does it take? - Image

Can Aging Biology Build a Business That Lasts Image

Can Aging Biology Build a Business That Lasts?

The latest women’s health venture capital news, updated monthly—tracking funding rounds of $3M or more across fertility & reproductive health, menopause & midlife, maternal health, oncology & diagnostics, endometriosis & hormonal conditions, and more.

Cure’s Women’s Health Funding Tracker 2026

Daré’s drug, the first pharmacologic treatment for HPV infection to reach a clinical trial, came out of three bold bets: repurposing a decades-old drug, skipping venture capital, and negotiating a new regulatory path with the FDA.

How Daré Got the First HPV Drug Into Trials, and What It Means for Women’s Health Founders

With no background in healthcare, Robert Gangi turned a Google search into a mission to stop ventilator-associated pneumonia (VAP), transforming an overlooked ICU problem into a venture-backed medical device company.

How a Google Search Became a Mission to Eliminate ICU Infections

The United States leads in scientific quality and commercial depth. China leads in speed, scale, and cost. Five analyses map both sides of the divide.

Thumbnail CII US v China 1200x675 - Image

Racing to Cures: The Cure U.S.-China Biotech Competitiveness Scorecard

These Boston area conferences bring together leading scientists, entrepreneurs, industry executives, and investors to share the latest research, explore therapeutic discoveries, and shape the future of medicines and therapies.

12 Best Biotech Conferences in Boston in 2026 

New York City is where Wall Street meets the biotech pipeline, forging deals that will help define the next decade of medicine. These conferences will get you in on the action.

Biotech Conferences in New York City Image

8 Best Biotech Conferences in NYC in 2026

Ten firms writing checks into women's health in 2026, from menopause and cardiovascular care to bone density, autoimmune disease, and oncology.

10 VCs Funding Women's Health Startups in 2026

A Q&A with the co-founder and CEO of Hi-Rx, a platform that connects pharmaceutical sponsors and clinical sites with on-demand nurses, on why clinical trial recruitment keeps breaking at the same point, and what a nurse network can do that a CRO can't.

Cure Member Spotlight: Russell Bar

From gene therapy to AI-driven target discovery, these eight firms are actively writing checks in rare disease biotech.

8 VCs Funding Rare Disease Startups in 2026

A Q&A with the founder of Rhizome AI, on why regulatory affairs teams are still searching PDFs by hand, and what it will take to give them something better.

Cure Member Spotlight: Chetan Mishra

From early-stage senolytics to AI-driven drug discovery, these seven firms are actively writing checks in longevity biotech.

VCs Funding Longevity and Anti-Aging Startups In 2026 - Image

VCs Funding Longevity and Anti-Aging Startups In 2026 - Image 02

7 VCs Funding Longevity Startups in 2026

The dates, locations, costs, and what to expect from 13 major biopharma and life sciences events, from ASCO to J.P. Morgan.

13 Key Biopharma Conferences in 2026-2027

Multi-modal AI, computational pathology, and liquid biopsy are converging and these companies are turning the promise of AI diagnostics into clinical reality.

9 Biotech Companies Using AI to Reshape Diagnostics

The latest medtech venture capital news, updated weekly—tracking major funding rounds of $10M or more in 2026.

Cure’s Medtech Funding Tracker 2026

Industry co-authorship can predict which academic research reaches the market, and the universities doing it best are not always the ones with the biggest research budgets.

10 Universities With the Best Biomedical Industry Connections

The race to reset the immune system, not just suppress it, is drawing a new generation of companies, and their approaches are more targeted than anything that came before.

10 Companies Making Major Advances in Autoimmune Disease

From RNA therapies to AI-enabled diagnostics, these companies are targeting one of medicine's biggest and most stubborn problems.

10 Biotech Companies Making Major Advances in Cardiovascular Disease

A Q&A with CEO of Genprex on the intravenous gene therapy platform behind Reqorsa, how the company is advancing pipelines in both lung cancer and diabetes, and what it still needs to prove.

Cure Member Spotlight: Ryan Confer

With 27 institutions ranked among the country’s top biomedical innovators, New York’s research cluster spans the entire state, and outperforms nearly every other in the country.

New York State Has Built One of the Country’s Most Powerful Biomedical Ecosystems

An overview of biotech funding and financing, from pre-seed groundwork to the questions investors actually ask before writing a check.

A Founder's Guide to Biotech Funding Image UPDATED

A Founder’s Guide to Biotech Funding

The latest biotech venture capital news, updated weekly—tracking major funding rounds of $10M or more in 2026.

Cure’s Biotech Funding Tracker 2026

Data from 303 U.S. institutions tracks the full path from discovery to commercialization, revealing wide variation among the nation’s top biomedical players.

CII-Launch CII Ranks America's Biomedical Research Institutions Image

Introducing the Cure Innovation Index, Ranking Institutions That Turn Discovery Into Medicine

Twenty universities ranked significantly higher in the Cure Innovation Index than their federal R&D spending would predict. Here's what they have in common.

CII-Launch - Institutions Punching Above Their Weight- Image

 Institutions Punching Above Their Weight

20 Universities Punching Above Their Weight in Biomedical Innovation

The data, the framework, and the decisions behind the first ranking of U.S. biomedical institutions on translational performance.

CII Prelaunch - Methodology How We Built the Cure Innovation Index - Image

Methodology How We Built the Cure Innovation Index - Image

Methodology: How We Built the Cure Innovation Index

The powerhouses lead, but the Index reveals translational strength in unexpected places.

CII-Launch - Top States For Biomedical Research - Image

Top 10 States for Biomedical Innovation

As part of the Cure Innovation Index, we surveyed 3,395 U.S. biomedical researchers to understand why discoveries aren't consistently commercialized and what the highest-performing institutions do differently.

CII-launch - What Makes an Institution Innovative? - Image

What Makes an Institution Innovative? A Cure Original Report

CII-Launch - Glossary - Image

Glossary

How the Cure Innovation Index evaluates the science, infrastructure, and funding behind biomedical discovery.

CII-Launch - Research Capabilities Domain Explainer - Image

Best in Research Capabilities

How the Cure Innovation Index evaluates whether institutions can move scientific discoveries to market.

CII-Launch - Market Translation Domain Explainer  - Image

Best in Market Translation

How the Cure Innovation Index measures whether institutions prepare researchers to move from discovery to venture.

CII Best in Entrepreneurial Readiness Image

Entrepreneurial Readiness Domain Explainer

Best in Entrepreneurial Readiness 

Most clinical trials fail, and the reasons extend far beyond the science. 

CII-Prelaunch - What's Standing Between a Promising Drug and the Patients Who Need It - Image

What's Standing Between a Promising Drug and the Patients Who Need It?

As NIH funding shrinks and industry pulls back from early-stage science, universities are rethinking how discoveries move from the lab to the market.

State of the Biotech Innovation Ecosystem

Universities Face an Uncertain Future as Gap To Industry Keeps Growing

A Q&A with Peter Farmakis, CEO of 32 Biosciences, on building a company around the biology most microbiome startups missed, and what it takes to move from academic science to a fundable, clinical-stage therapeutic.

Cure Member Spotlight: Peter Farmakis Image

Cure Member Spotlight: Peter Farmakis

Federal grants are vanishing and VC dollars are concentrating at the top. For early-stage biotech founders, the path from lab to funding looks nothing like it did five years ago.

Who Is Funding the Science That's Too Early for Venture Capital?

The Bayh-Dole Act turned federally funded research into a commercialization pipeline that built American biotech. Forty-five years later, that pipeline faces a new set of political and financial pressures that could reshape how it works.

CII-Pre-Launch-How Universities Became the Engine of the Biotech Industry- Image

How Universities Became the Engine of the Biotech Industry

These companies are building procedure-driven devices with a clear path to FDA clearance and commercialization.

8 MedTech Startups to Watch in 2026

A Q&A with Larry Raoul James, CEO and President of MindLab, on why the opioid crisis was a drug design problem, and what it takes to build a next-generation pain therapeutic in a challenging category.

Cure Member Spotlight: Larry Raoul James Image

Cure Member Spotlight: Larry Raoul James

From ambient scribes to revenue cycle automation, these companies stand out for their solutions to healthcare's most persistent operational and clinical bottlenecks.

11 AI Companies Reshaping Healthcare Delivery and Clinical Workflows In 2026

As next-generation editing tools move from bench to bedside, these ten companies are leading the charge toward a new era of genetic medicine.

10 CRISPR Companies to Watch in 2026

Stem cell therapies are moving out of the lab and into the clinic, with early trials showing real signal and regulators opening faster paths to approval. These companies pushing the field toward standard care.

Stem Cell Companies to Watch in 2026 - Image Updated

10 Stem Cell Companies to Watch in 2026

A Q&A with Irene Rombel, Co-Founder and CEO of BioCurie, on why manufacturing—not discovery—is the real bottleneck in cell and gene therapy, and what it takes to build an AI-driven software company at the frontier of genomic medicine.

Cure Member Spotlight: Irene Rombel, PhD

The maternal health startup won $100,000 in equity investment from the Catalytic Impact Foundation at Cure's Power of X Summit.

DeepEcho Wins Second Annual CIF Prize in Women's Health

From early IP decisions to FDA strategy and investor negotiations, a biotech company’s legal needs shift quickly as it grows. Here’s how founders can build the right legal foundation, avoid common missteps, and bring in the right counsel at the right time.

The Legal Playbook for Building a Biotech Company, From Formation to Financing

Cure’s Power of X Summit, held on March 18–19, had a clear throughline: women’s health has moved from a long-standing thesis to a category with proof, traction, and capital behind it.

The Key Takeaways From Cure's Power of X: Women's Health Innovation Summit 2026

From AI-driven diagnostics to next-generation targeted therapies, these startups are redefining how cancer is understood, matched, and treated at the molecular level.

12 Biotech Companies Making Advances in Precision Oncology

The startup is using insights from the Cure by Deerfield Middle East Health Accelerator to refine its care model and expand access to pediatric endocrinology across new markets.

Virginia-Based EndoMD Builds Momentum After Third-Place Finish in Cure Accelerator

From self-amplifying RNA to programmable, cell-selective therapies, a new class of biotech companies is pushing mRNA beyond vaccines and into precision medicine across cancer, rare disease, and chronic conditions.

8 Biotech Companies Driving Breakthroughs in mRNA Vaccines

A Q&A with Oriana Zinani, PhD, Co-Founder and CEO of Applied PharmacoDynamics, on the science behind APD’s lead program for cocaine use disorder and what it takes to advance a first-in-class therapy in an area with enormous unmet need.


Cure Member Spotlight: Oriana Zinani, PhD

Moving a discovery from the lab to large-scale manufacturing requires far more than a handoff. Experts explain how technology transfer works in biotech and pharma, the different types of transfers, and why poor execution can delay commercialization.

Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines

Investment in women’s health is accelerating as founders build solutions that address longstanding gaps in care. These nine startups are developing technologies and care models that span fertility, maternal health, menopause, and healthy aging.

9 Women’s Health Startups to Watch in 2026 

Landing a job in biotech takes more than strong science credentials. Recruiters and founders explain what companies look for and how candidates can position themselves to break into the industry.

How to Get a Job in Biotech: A Career Guide for Scientists and Industry Entrants

After placing second at the Cure by Deerfield Middle East Health Accelerator in Qatar, NYC-based biotech VentriNaya is advancing its regenerative gene and cell therapy programs for cardiovascular disease while preparing for fundraising and regulatory milestones.

NYC-Based Gene and Cell Therapy Startup Builds Momentum After Runner-Up Finish in Cure Accelerator

A Q&A with Matt Lewis, CEO of Transformental, on why most AI transformations fail for human reasons, how healthcare organizations build “brain capital,” and what it takes to introduce AI responsibly in high-stakes environments.

Cure Member Spotlight: Matt Lewis Image

Cure Member Spotlight: Matt Lewis

Explore Seattle's most impactful biotech and life sciences companies, and learn why Washington continues to be one of the nation’s leading states for biopharma investment.

9 Biggest Biotech and Life Science Companies In Seattle

Business coach Chris Westfall explains why founders should resist making a formal mentorship ask too soon, and how to test for alignment, invite candid feedback, and build a relationship that sharpens strategy over time.

The Smarter Way to Find a Mentor for Your Startup, According to a Business Coach

After taking first place at The Cure by Deerfield Middle East Health Accelerator’s Demo Day, Atomistic Insights is establishing a presence in Qatar and exploring co-discovery partnerships, as it advances its physics-driven AI platform for drug development.

After Accelerator Win, Atlanta-Based AI Drug Discovery Startup Eyes Growth in Qatar

Ahead of this year's Catalytic Impact Foundation's pitch competition at the Power of X Summit, we checked in with last year's winners LunaJoy, Limax Biosciences, and Flourish Care, who have spent the past year scaling care delivery and advancing their missions.

Last Year’s CIF Impact Challenge Winners Put Funding to Work in Women’s Health

The Minneapolis-St. Paul region is experiencing a lot of growth in the biotech and life-sciences industry. Here are eight of the biggest biotech companies with connections to the area.

8 Biggest Biotech and Life Science Companies in Minneapolis and St. Paul

Nolan Townsend, CEO of Lexeo Therapeutics, shares candid lessons on how IPOs reshape investor relationships, disclosure strategy, and the day-to-day responsibilities of leading a public biotech company.

A Biotech CEO on How Going Public Reshapes the Role

Explore North Carolina’s most impactful biotech and life sciences companies, and learn why the state's Research Triangle Park (RTP), in particular, continues to be one of the nation’s leading hubs for biopharma investment and growth.

12 Biggest Biotech and Life Science Companies in North Carolina’s Research Triangle

For biotech startups, patient data is both a competitive edge and a legal risk. Experts explain how to collect, store, and use it responsibly without slowing growth.

Patient Data Is an Asset and a Liability—Here’s How to Avoid Costly Missteps

Explore the biggest biotech companies in the San Francisco Bay Area and see how the region’s mix of top research institutions, venture capital, and AI expertise keeps it at the center of global life sciences, even amid funding pressure and market recalibration.

11 Biggest Biotech Companies in the Bay Area

From AI-native care models to regulatory whiplash and new pressures around coverage and privacy, Out-of-Pocket Health founder Nikhil Krishnan lays out the forces expected to reshape biotech in the year ahead.

5 Ways Biotech Will Change in 2026, According to Nikhil Krishnan

Three biotech and digital health startups emerged as winners of Cure’s MEHA Demo Day, reflecting the region’s growing healthcare innovation ecosystem.

Cure’s Middle East Health Accelerator Picks Three Startups with Potential to Scale in the Region

Explore the biggest and most groundbreaking biotech companies in San Diego, and discover why the region remains one of the most vibrant life science hubs in the US.

11 Biggest Biotech Companies in San Diego

Lessons from Wandercraft CEO Matthieu Masselin on how risk, reimbursement, and regulation fundamentally change when scaling a healthcare company across Europe and the US.

The Key Differences Between Building a Healthcare Company in the US vs Europe

Patient focus groups can surface powerful insight or quietly mislead early decisions. Experts share tips for biotech teams on how to design and run focus groups that generate real, actionable input while respecting patient autonomy.

Patient Focus Groups Drive Better Research—Here's How to Get Real Insights

Salt Lake City’s biotech and life-sciences industry is experiencing a lot of growth. Here are eight of the biggest biotech companies with connections to the area.

7 Biggest Biotech Companies in Salt Lake City

Regulators and investors still want clean data, but patients want proof a therapy changes daily life. Here’s how early-stage biotech teams can choose endpoints that are measurable, meaningful, and feasible.

Patient-Centered Endpoints for Biotech Startups: Choosing Outcomes That Matter in the Real World

A Q&A with Karolyn Chamberlin, COO of Rarecells, on the science behind ISET, why whole circulating tumor cells matter for early cancer detection, and the challenge of translating decades of academic research into clinical impact.

Cure Member Spotlight: Karolyn Chamberlin

Clare Peeters, CBO and CFO of The New York Academy of Sciences, shares why a small set of financial metrics should stay top of mind for healthcare founders.

3 Key Financial Metrics That Decide the Fate of Your Company

Meet the latest founders, investors, and operators joining the Cure community, spanning biotech, medtech, AI, and healthcare services.

Meet the Founders, Investors, and Operators Joining the Cure Community

What's new

Blue

Explore the latest insights in healthcare innovation, featuring articles on cutting-edge research, trends, and success stories from industry leaders.

Cure’s Biotech Funding Tracker 2026

Cure Original Report: The Core Labs Behind the Deals

Your Home in NYC

Where Healthcare Innovators Connect

Accelerating Advances in Health

How will you advance healthcare?

What's new

Featured

How Protara Built a Biotech Around Second-Chance Drugs

Join the Cure Community

Cure Email

This Week in Healthcare Innovation

Cure Innovation Index Original Report

The Core Labs Behind the Deals

Cure Original Reports